(NASDAQ: IPSC) Century Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.9%.
Century Therapeutics's earnings in 2025 is -$129,893,000.On average, 5 Wall Street analysts forecast IPSC's earnings for 2025 to be -$149,140,940, with the lowest IPSC earnings forecast at -$168,357,503, and the highest IPSC earnings forecast at -$120,741,240. On average, 1 Wall Street analyst forecast IPSC's earnings for 2026 to be -$186,213,602, with the lowest IPSC earnings forecast at -$186,213,602, and the highest IPSC earnings forecast at -$186,213,602.
In 2027, IPSC is forecast to generate -$102,885,141 in earnings, with the lowest earnings forecast at -$102,885,141 and the highest earnings forecast at -$102,885,141.